Mind Medicine (MindMed) Past Earnings Performance
Past criteria checks 0/6
Mind Medicine (MindMed)'s earnings have been declining at an average annual rate of -23.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Key information
-23.7%
Earnings growth rate
1.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -63.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Mind Medicine (MindMed) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -125 | 44 | 51 |
| 31 Dec 23 | 0 | -96 | 42 | 52 |
| 30 Sep 23 | 0 | -77 | 36 | 49 |
| 30 Jun 23 | 0 | -75 | 37 | 44 |
| 31 Mar 23 | 0 | -63 | 30 | 39 |
| 31 Dec 22 | 0 | -57 | 30 | 36 |
| 30 Sep 22 | 0 | -69 | 32 | 38 |
| 30 Jun 22 | 0 | -69 | 31 | 39 |
| 31 Mar 22 | 0 | -98 | 60 | 38 |
| 31 Dec 21 | 0 | -93 | 59 | 35 |
| 30 Sep 21 | 0 | -89 | 59 | 32 |
| 30 Jun 21 | 0 | -80 | 53 | 29 |
| 31 Mar 21 | 0 | -41 | 19 | 24 |
| 31 Dec 20 | 0 | -34 | 14 | 19 |
| 30 Sep 20 | 0 | -29 | 11 | 14 |
Quality Earnings: MMQ is currently unprofitable.
Growing Profit Margin: MMQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MMQ is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare MMQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MMQ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: MMQ has a negative Return on Equity (-63.92%), as it is currently unprofitable.